Minimal residual disease after allogeneic bone marrow transplantation for chronic myeloid leukaemia: A metaphase-FISH study

Wael El-Rifai, Tapani Ruutu, Kim Vettenranta, Samia Temtamy, Sakari Knuutila

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Metaphase-FISH was adopted for the detection of proliferating Philadelphia-positive (Ph+) residual leukaemic cells in 25 patients with chronic myeloid leukaemia treated with allogeneic bone marrow transplantation (BMT). Patients were followed up during their clinical remission for 4-50 months (median 17 months) after BMT. 80 bone marrow samples were studied. For most of the cases no fewer than 1000 metaphases were analysed. Six patients (24%) showed residual Ph+ cells during the first 6 months and two others by the end of the first year after BMT. Three patients relapsed during the study and in two of them residual Ph+ cells were detected during the first 6 months after BMT. In 17 patients no Ph+ cells were detected at any stage of follow-up and 16 (94.1%) of them continue in complete clinical and haematological remission. Our results indicate that metaphase-FISH is a reliable tool in the quantitation of proliferating residual leukaemic cells. We suggest that consecutive findings of equal amounts of residual leukaemic cells do not necessarily predict a relapse. However, their presence calls for follow-up at shorter intervals where an increasing number of these cells predicts an ensuing relapse.

Original languageEnglish (US)
Pages (from-to)365-369
Number of pages5
JournalBritish Journal of Haematology
Volume92
Issue number2
DOIs
StatePublished - Jan 1 1996
Externally publishedYes

Fingerprint

Homologous Transplantation
Residual Neoplasm
Metaphase
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Bone Marrow Transplantation
Recurrence
Cell Count
Bone Marrow

Keywords

  • Chronic myeloid leukaemia
  • Minimal residual disease
  • Nuorescence in situ hybridization

ASJC Scopus subject areas

  • Hematology

Cite this

Minimal residual disease after allogeneic bone marrow transplantation for chronic myeloid leukaemia : A metaphase-FISH study. / El-Rifai, Wael; Ruutu, Tapani; Vettenranta, Kim; Temtamy, Samia; Knuutila, Sakari.

In: British Journal of Haematology, Vol. 92, No. 2, 01.01.1996, p. 365-369.

Research output: Contribution to journalArticle

El-Rifai, Wael ; Ruutu, Tapani ; Vettenranta, Kim ; Temtamy, Samia ; Knuutila, Sakari. / Minimal residual disease after allogeneic bone marrow transplantation for chronic myeloid leukaemia : A metaphase-FISH study. In: British Journal of Haematology. 1996 ; Vol. 92, No. 2. pp. 365-369.
@article{3dd66852d94645da9ca91d89c7b13b3a,
title = "Minimal residual disease after allogeneic bone marrow transplantation for chronic myeloid leukaemia: A metaphase-FISH study",
abstract = "Metaphase-FISH was adopted for the detection of proliferating Philadelphia-positive (Ph+) residual leukaemic cells in 25 patients with chronic myeloid leukaemia treated with allogeneic bone marrow transplantation (BMT). Patients were followed up during their clinical remission for 4-50 months (median 17 months) after BMT. 80 bone marrow samples were studied. For most of the cases no fewer than 1000 metaphases were analysed. Six patients (24{\%}) showed residual Ph+ cells during the first 6 months and two others by the end of the first year after BMT. Three patients relapsed during the study and in two of them residual Ph+ cells were detected during the first 6 months after BMT. In 17 patients no Ph+ cells were detected at any stage of follow-up and 16 (94.1{\%}) of them continue in complete clinical and haematological remission. Our results indicate that metaphase-FISH is a reliable tool in the quantitation of proliferating residual leukaemic cells. We suggest that consecutive findings of equal amounts of residual leukaemic cells do not necessarily predict a relapse. However, their presence calls for follow-up at shorter intervals where an increasing number of these cells predicts an ensuing relapse.",
keywords = "Chronic myeloid leukaemia, Minimal residual disease, Nuorescence in situ hybridization",
author = "Wael El-Rifai and Tapani Ruutu and Kim Vettenranta and Samia Temtamy and Sakari Knuutila",
year = "1996",
month = "1",
day = "1",
doi = "10.1046/j.1365-2141.1996.d01-1507.x",
language = "English (US)",
volume = "92",
pages = "365--369",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - Minimal residual disease after allogeneic bone marrow transplantation for chronic myeloid leukaemia

T2 - A metaphase-FISH study

AU - El-Rifai, Wael

AU - Ruutu, Tapani

AU - Vettenranta, Kim

AU - Temtamy, Samia

AU - Knuutila, Sakari

PY - 1996/1/1

Y1 - 1996/1/1

N2 - Metaphase-FISH was adopted for the detection of proliferating Philadelphia-positive (Ph+) residual leukaemic cells in 25 patients with chronic myeloid leukaemia treated with allogeneic bone marrow transplantation (BMT). Patients were followed up during their clinical remission for 4-50 months (median 17 months) after BMT. 80 bone marrow samples were studied. For most of the cases no fewer than 1000 metaphases were analysed. Six patients (24%) showed residual Ph+ cells during the first 6 months and two others by the end of the first year after BMT. Three patients relapsed during the study and in two of them residual Ph+ cells were detected during the first 6 months after BMT. In 17 patients no Ph+ cells were detected at any stage of follow-up and 16 (94.1%) of them continue in complete clinical and haematological remission. Our results indicate that metaphase-FISH is a reliable tool in the quantitation of proliferating residual leukaemic cells. We suggest that consecutive findings of equal amounts of residual leukaemic cells do not necessarily predict a relapse. However, their presence calls for follow-up at shorter intervals where an increasing number of these cells predicts an ensuing relapse.

AB - Metaphase-FISH was adopted for the detection of proliferating Philadelphia-positive (Ph+) residual leukaemic cells in 25 patients with chronic myeloid leukaemia treated with allogeneic bone marrow transplantation (BMT). Patients were followed up during their clinical remission for 4-50 months (median 17 months) after BMT. 80 bone marrow samples were studied. For most of the cases no fewer than 1000 metaphases were analysed. Six patients (24%) showed residual Ph+ cells during the first 6 months and two others by the end of the first year after BMT. Three patients relapsed during the study and in two of them residual Ph+ cells were detected during the first 6 months after BMT. In 17 patients no Ph+ cells were detected at any stage of follow-up and 16 (94.1%) of them continue in complete clinical and haematological remission. Our results indicate that metaphase-FISH is a reliable tool in the quantitation of proliferating residual leukaemic cells. We suggest that consecutive findings of equal amounts of residual leukaemic cells do not necessarily predict a relapse. However, their presence calls for follow-up at shorter intervals where an increasing number of these cells predicts an ensuing relapse.

KW - Chronic myeloid leukaemia

KW - Minimal residual disease

KW - Nuorescence in situ hybridization

UR - http://www.scopus.com/inward/record.url?scp=0030026450&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030026450&partnerID=8YFLogxK

U2 - 10.1046/j.1365-2141.1996.d01-1507.x

DO - 10.1046/j.1365-2141.1996.d01-1507.x

M3 - Article

C2 - 8603001

AN - SCOPUS:0030026450

VL - 92

SP - 365

EP - 369

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 2

ER -